Tests SHR-1826 in adults with advanced non-small cell lung cancer
Tests the drug SHR-1826 in adults with advanced non-small cell lung cancer.
Key facts
- Who runs it
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Where
- Jinan, ChinaSee the site
- Trial code
- Registry title
- A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 90 people, planned
- Started
- 29 Apr 2026
- Expected to end
- Dec 2028
- Type of study
- Interventional
- Treatments tested
- SHR-1826
- Record updated
- 13 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18-75 with advanced or metastatic non-small cell lung cancer whose disease got worse or who could not tolerate earlier cancer treatment.
- Age
- 18 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Advanced or metastatic non-small cell lung cancer, confirmed under the microscope, with at least one measurable tumour (RECIST v1.1). ECOG performance status 0 or 1. Expected survival of at least 3 months.
- Earlier treatment
- Must have had disease progression or intolerance after systemic anti-tumor therapy for advanced or metastatic disease.
- Biomarker or test result
- Must provide archived or fresh tumor tissue.
Main reasons for not taking part
- Brain or meningeal spread of cancer that causes symptoms
- Another cancer now or in the past
- Untreated spinal cord compression
- Uncontrolled pain from the tumour
- History of interstitial lung disease
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Aged 18-75 years
- ECOG performance status score of 0 or 1
- Histopathologically confirmed advanced or metastatic non-small cell lung cancer
- Participants must provide archived or fresh tumor tissue
- Participants must have experienced disease progression or intolerance after systemic anti-tumor therapy for advanced or metastatic disease
- At least one measurable lesion according to RECIST v1.1 criteria
- Expected survival ≥3 months
- Adequate organ function
Who cannot take part
- History of or concurrent other malignancies
- Adverse events (AEs) from prior therapy not recovered to CTCAE Grade ≤1
- History of interstitial lung disease
- Severe cardiovascular/cerebrovascular diseases
- Central nervous system metastasis or meningeal metastasis with clinical symptoms
- Untreated spinal cord compression
- Uncontrolled tumor-related pain
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in China
- Affiliated Cancer Hospital of Shandong First Medical UniversityJinan, ChinaContact: Jinming Yu (principal investigator)Taking people
About the trial
What the trial wants to find out
This study is a single-arm, open-label, multicenter phase II clinical trial aimed at evaluating the efficacy, safety, and pharmacokinetics of SHR-1826 in treating locally advanced or metastatic non-small cell lung cancer . The recommended dose of SHR-1826 was administered via intravenous infusion once every 3 weeks (Q3W), with each treatment cycle lasting 21 days until meeting protocol-defined treatment discontinuation criteria.
The group in the trial
- SHR-1826Treatment being tested
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase II Clinical Study on the Efficacy, Safety, and Pharmacokinetics of SHR-1826 for Injection in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Plain-language title
- Tests SHR-1826 in adults with advanced non-small cell lung cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07489716, who can take part
- Record updated
- 13 May 2026